About Uniqure NV
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: NL
- Website: https://www.uniqure.com/
Frequently Asked Questions
What is the 52-week range for QURE?
The 52-week high is $71.5 and the 52-week low is $8.73.
What is the P/E ratio for QURE?
The P/E ratio data is currently unavailable.
What is the dividend yield for QURE?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -111.96%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -1350.73%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 7.41.
Analyst Recommendation Trends
Wall Street analyst consensus for QURE over the last few months:
Latest QURE News
RBC Capital Maintains Outperform on uniQure, Lowers Price Target to $48
RBC Capital analyst Luca Issi maintains uniQure (NASDAQ:QURE) with a Outperform and lowers the price target from $65 to $48.
ClearPoint Neuro: My Speculative Buy Didn't Pan Out, Moving To Hold
ClearPoint Neuro faces heightened uncertainty after uniQure's AMT-130 48-month data disappointed. Read more on CLPT stock here.
uniQure (QURE) Faces A Fresh AMT 130 Test After Mixed Data, Bargain Or Trap
uniQure (NasdaqGS:QURE) is back in focus after new 36- and 48-month data for its Huntington’s gene therapy, AMT-130, sparked sharp swings in the share price and renewed debate about the program. uniQure’s share price has been hit hard in the wake of the mixed AMT-130 update, with a 7-day share price return down 36.95% and a 30-day move down 49.52%, even though the year-to-date share price return is still up 3.29% and the 3-year total shareholder return is very large at roughly 2.6x. This...
uniQure Plunges on Additional Data From Huntington's Disease Study
QURE's Huntingtons gene therapy shows sustained functional benefits at 36 months, but mixed 48-month data add uncertainty.
uniQure Stock Crashed on Its Huntington’s Data. Wall Street’s Price Target Says the Selloff Went Too Far
uniQure lost more than a third of its value in a single session after Huntington's data spooked investors, but Wall Street's price target still points to triple-digit upside. Whether that gap represents opportunity or denial depends on one number that cuts both ways.
uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data Update
The bullish thesis for uniQureâs gene therapy for Huntington's disease is still intact, as evident in consistent and positive TFC data. Click for more on QURE.
Goldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $31
Goldman Sachs analyst Salveen Richter maintains uniQure (NASDAQ:QURE) with a Neutral and lowers the price target from $46 to $31.
Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday
U.S. stocks rose as Nasdaq gained 100+ points; HPE jumped 5.1% on stronger networking guidance and a Vultr AI rack order.
uniQure Stock Plunges On 4-Year Data, But The Approval Path Is Intact (Rating Upgrade)
uniQure upgraded to speculative Buy as FDA aligns on BLA path for Huntingtonâs gene therapy. Click for more on QURE stock.
QURE Stock Clocks Worst Day In Over 10 Months: Four-Year Huntington’s Data Spooks Investors Despite Stronger Three-Year Filing Data
uniQure said AMT-130 continued to slow Huntington’s disease in ongoing early- and mid-stage studies after four years.
Uniqure Plummets 37% On Another Shocking Twist For Its Huntington's Drug
Uniqure stock plummeted Tuesday on a disappointing four-year update for its experimental gene therapy in patients with Huntington's disease.
uniQure BLA Filed as AMT-130 Shows 4-Year Huntington’s Functional Benefit
uniQure (NASDAQ:QURE) reported updated Phase I/II data for its investigational Huntington’s disease gene therapy, ifezuntirgene inilparvovec, or AMT-130, including 36-month results from all high-dose patients and 48-month results from the first 12 high-dose patients to reach that milestone. The com
Top movers analysis one hour before the close of the markets on 2026-09-29: top gainers and losers in today's session.
Looking for insights into the US markets one hour before the close of the markets on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
These stocks are moving in today's session
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
uniQure N.V. (QURE) Discusses Additional Data from Phase I/II AMT-130 Study in Huntington's Disease Highlighting Disease Progression Slowing Transcript
uniQure N.V. (QURE) Discusses Additional Data from Phase I/II AMT-130 Study in Huntington's Disease Highlighting Disease Progression Slowing September 29,...
uniQure: Another Selloff On 48-Month Huntington Data; I Am (Marginally) Bullish
uniQure's BLA for AMT-130 is anchored on robust 36-month data, with the FDA signaling willingness to review. Click to read more about the Buy rating for QURE.
Traders are paying attention to the gapping stocks in Tuesday's session.
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.
Why Is uniQure Stock Sinking on Tuesday?
uniQure N.V. (NASDAQ:QURE) stock is trading lower on Tuesday after the company shared mixed long-term data from ongoing Phase 1/2 clinical studies evaluating ifezuntirgene inilparvovec for Huntington’s disease. 36-Month Clinical Results And BLA Pathway In the 36-month analysis, high-dose patients demonstrated an 80% slowing of disease progression on the Composite Unified Huntington’s Disease Rating Scale (cUHDRS) and a 67% slowing on Total Functional Capacity (TFC). cUHDRS is a specialized scori
UniQure Insists Huntington’s Drug Is Still on Track as Stock Plunges 36%
UniQure says it still sees a path to regulatory approval for the drug candidate, AMT-130, even as the experimental gene therapy for Huntington’s disease falls hort in a recent study.
uniQure N.V. (QURE) Discusses Additional Data from Phase I/II AMT-130 Study in Huntington's Disease Highlighting Disease Progression Slowing - Slideshow
2026-09-29. The following slide deck was published by uniQure N.V.
uniQure Shares Fall 64% After 48-Month AMT-130 Huntington’s Disease Trial Update
uniQure N. V. (NASDAQ:QURE) shares fell 64% on Tuesday after the gene therapy developer reported updated 48-month data for ifezuntirgene inilparvovec, or AMT-130, its experimental treatment for Huntington’s disease.
ClearPoint Neuro Shares Fall 24% Following uniQure AMT-130 Trial Update
ClearPoint Neuro (NASDAQ:CLPT) shares fell 24% on Tuesday following updated clinical trial results from partner uniQure N. V.
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Stablecoin Development (AMEX:SDEV) stock increased by 121.6% to $3.48 during Tuesday's regular session. The market value of their outstanding shares is at $42.5 million. Iovance Biotherapeutics
QURE Stock Is On Track To Shed About Half Its Market Cap Despite Encouraging Huntington’s Disease Data – Here’s What Investors Need To Know
uniQure’s Ifezuntirgene slowed disease progression by 80% on a measure combining movement, thinking and daily function.
These stocks that are showing activity before the opening bell on Tuesday.
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Crude Oil Down 1%; US Job Openings Fall In August
U.S. stocks fell as job openings declined; oil slid and gold rose. BKYI doubled, SSTI surged, while NIVF plunged 77% and QURE fell 37%.
uniQure plunges 65% as 48-month Huntington’s gene therapy data misses key stat
Investing.com -- Shares of gene therapy developer uniQure N.V. (NASDAQ: QURE) cratered 64% Tuesday morning following an updated data readout for its experimental Huntington’s disease treatment, ifezuntirgene inilparvovec (AMT-130). While the treatment continued to show a dose-dependent slowing of disease progression, a failure to hit statistical significance on a primary clinical measure at 48 months triggered a massive sell-off.
uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression
~ In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear dose-dependent response; the primary endpoint of cUHDRS showed 44% slowing of disease progression (non-significant p=0.144) and TFC showed a 61% slowing of disease progression (nominal p=0.008) ~ ~ Updated data reflecting all 15 high-dose patients showed substantial treatment effect on both cUHDRS and TFC at 36 months, the timepoint that is the regulatory anch
Dow Tumbles 100 Points; Carnival Posts Upbeat Q3 Earnings
U.S. stocks were mixed; Dow and S&P 500 fell while Nasdaq edged up. Carnival beat estimates. BIO-Key surged 127%; oil dropped 2%.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 26.8% to $0.32 during Tuesday's pre-market session. The company's market cap stands at $1.3 million. Summit Therapeutics (NASDAQ:SMMT) stock rose 16.34%
uniQure Announces Additional Data From Ongoing Phase I/II Studies Of Ifezuntirgene Inilparvovec For Treatment Of Huntington’s Disease; In 12 High-Dose Patients At 48 Months, Both cUHDRS And TFC Continued To Demonstrate Meaningful Slowing Of Disease Progression And Clear Dose-Dependent Response; Primary Endpoint Of cUHDRS Showed 44% Slowing Of Disease Progression
~ In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear dose-dependent response; the primary endpoint of cUHDRS showed 44% slowing of
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
Novo has 44 abstracts at EASD, including CagriSema analyses and Phase 2b Zenagamtide results.
Micron, Nike To Headline Earnings Next Week; GDP Numbers Awaited
Wall Street Week Ahead: key market events, earnings (MU, NKE), IPOs (OURA), and major economic data. See here for more details.
uniQure (QURE) Submitted AMT-130 for Accelerated Approval in Huntington’s Disease. Can Externally Controlled Data Support the Application?
uniQure N.V. (NASDAQ:QURE) submitted a biologics license application, or BLA, to the U.S. Food and Drug Administration for accelerated approval of ifezuntirgene inilparvovec, formerly AMT-130, in Huntington’s disease. uniQure N.V. (NASDAQ:QURE) also requested priority review, which would provide a six-month review cycle after the FDA completes its 60-day filing review if granted. The application’s clinical-efficacy […]
ClearPoint Neuro (CLPT) Stock Sees Fair Value Cut As Analysts Factor In Heavier Investment
Price targets for ClearPoint Neuro have shifted toward the low to mid US$20s, with the average assessed fair value moving from US$28.33 to US$23.50 and one outlier still at US$30. Analysts link this change to a period they see as more investment heavy, balancing optimism about long term growth potential with caution around near term execution and partner related contributions. As you read on, you will see how this evolving narrative could shape the way you track ClearPoint Neuro from...
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-02 | Kapusta Matthew C | -21,082 | - | - |
| 2026-07-02 | Kapusta Matthew C | -7,600 | $45.89 | $348,764 |
| 2026-07-02 | Kapusta Matthew C | -4,282 | $45.43 | $194,531 |
| 2026-07-02 | Kapusta Matthew C | -9,200 | $44.43 | $408,756 |
| 2026-07-02 | Kapusta Matthew C | +21,082 | $19.39 | $408,780 |
| 2026-06-30 | Abi-Saab Walid | -10,000 | - | - |
| 2026-06-30 | Abi-Saab Walid | -20,000 | $46.4 | $928,000 |
| 2026-06-30 | Abi-Saab Walid | -10,000 | $46.46 | $464,600 |
| 2026-06-30 | Abi-Saab Walid | +10,000 | $5.59 | $55,900 |
| 2026-06-30 | Kaye Jack | -17,060 | - | - |
| 2026-06-30 | Kaye Jack | -4,107 | - | - |
| 2026-06-30 | Kaye Jack | -17,060 | $46.43 | $792,096 |
| 2026-06-30 | Kaye Jack | +17,060 | $20.18 | $344,271 |
| 2026-06-30 | Kaye Jack | -4,107 | $46.49 | $190,934 |
| 2026-06-30 | Kaye Jack | +4,107 | $37 | $151,959 |
| 2026-06-25 | Kapusta Matthew C | -28,716 | - | - |
| 2026-06-25 | Kapusta Matthew C | -28,716 | $50.02 | $1,436,374 |
| 2026-06-25 | Kapusta Matthew C | +28,716 | $31.71 | $910,584 |
| 2026-06-24 | Kapusta Matthew C | -4,128 | - | - |
| 2026-06-24 | Kapusta Matthew C | -6,696 | $50 | $334,800 |
| 2026-06-24 | Kapusta Matthew C | +4,128 | $31.71 | $130,899 |
| 2026-06-18 | Kapusta Matthew C | -4,656 | - | - |
| 2026-06-18 | Kapusta Matthew C | -37,015 | $50 | $1,850,750 |
| 2026-06-18 | Kapusta Matthew C | -4,656 | $50 | $232,800 |
| 2026-06-18 | Kapusta Matthew C | +4,656 | $31.71 | $147,642 |
| 2026-06-17 | Balachandran Madhavan | -6,390 | - | - |
| 2026-06-17 | Balachandran Madhavan | -5,295 | - | - |
| 2026-06-17 | Balachandran Madhavan | -1,690 | $42.6 | $71,994 |
| 2026-06-17 | Balachandran Madhavan | -4,700 | $43.66 | $205,202 |
| 2026-06-17 | Balachandran Madhavan | -5,295 | $47.08 | $249,289 |
| 2026-06-17 | Balachandran Madhavan | +6,390 | $19.39 | $123,902 |
| 2026-06-17 | Balachandran Madhavan | +5,295 | $31.71 | $167,904 |
| 2026-06-17 | Kapusta Matthew C | -62,581 | - | - |
| 2026-06-17 | Kapusta Matthew C | -11,585 | $48.65 | $563,610 |
| 2026-06-17 | Kapusta Matthew C | -33,334 | $45.01 | $1,500,363 |
| 2026-06-17 | Kapusta Matthew C | -56,929 | $43.43 | $2,472,426 |
| 2026-06-17 | Kapusta Matthew C | -32,581 | $45.02 | $1,466,797 |
| 2026-06-17 | Kapusta Matthew C | -6,023 | $43.7 | $263,205 |
| 2026-06-17 | Kapusta Matthew C | -23,977 | $42.61 | $1,021,660 |
| 2026-06-17 | Kapusta Matthew C | +62,581 | $19.39 | $1,213,446 |
| 2026-06-17 | Kaye Jack | -5,295 | - | - |
| 2026-06-17 | Kaye Jack | -5,295 | $42.57 | $225,408 |
| 2026-06-17 | Kaye Jack | +5,295 | $31.71 | $167,904 |
| 2026-06-15 | Potts Jeannette | -5,237 | $27.67 | $144,908 |
| 2026-06-15 | Balachandran Madhavan | -10,000 | - | - |
| 2026-06-15 | Balachandran Madhavan | -10,000 | $27.85 | $278,500 |
| 2026-06-15 | Balachandran Madhavan | +10,000 | $8.49 | $84,900 |
| 2026-06-11 | Gut Robert | -2,726 | $27.06 | $73,766 |
| 2026-06-11 | O'Keefe Kylie | -15,936 | $27.06 | $431,228 |
| 2026-06-11 | Springhorn Jeremy P. | -1,993 | $27.06 | $53,931 |
| 2026-06-11 | Jacques Rachelle Suzanne | -1,993 | $27.06 | $53,931 |
| 2026-06-11 | Balachandran Madhavan | -1,993 | $27.06 | $53,931 |
| 2026-06-11 | Meek David D. | -1,993 | $27.06 | $53,931 |
| 2026-06-11 | Kaye Jack | -1,993 | $27.06 | $53,931 |
| 2026-06-11 | POST LEONARD E | -1,993 | $27.06 | $53,931 |
| 2026-06-10 | Gut Robert | +13,980 | - | - |
| 2026-06-10 | Gut Robert | -2,645 | - | - |
| 2026-06-10 | Gut Robert | +7,550 | - | - |
| 2026-06-10 | Gut Robert | -1,780 | $26.05 | $46,369 |
| 2026-06-10 | Gut Robert | -3,127 | $26.03 | $81,396 |
| 2026-06-10 | Gut Robert | -2,645 | $26.07 | $68,955 |
| 2026-06-10 | Gut Robert | +2,645 | $16.04 | $42,426 |
| 2026-06-10 | Springhorn Jeremy P. | +13,980 | - | - |
| 2026-06-10 | Springhorn Jeremy P. | +7,550 | - | - |
| 2026-06-10 | Jacques Rachelle Suzanne | +13,980 | - | - |
| 2026-06-10 | Jacques Rachelle Suzanne | +7,550 | - | - |
| 2026-06-10 | Balachandran Madhavan | +13,980 | - | - |
| 2026-06-10 | Balachandran Madhavan | +7,550 | - | - |
| 2026-06-10 | Meek David D. | +13,980 | - | - |
| 2026-06-10 | Meek David D. | +7,550 | - | - |
| 2026-06-10 | Kaye Jack | +13,980 | - | - |
| 2026-06-10 | Kaye Jack | +7,550 | - | - |
| 2026-06-10 | POST LEONARD E | +13,980 | - | - |
| 2026-06-10 | POST LEONARD E | +7,550 | - | - |
| 2026-06-03 | Kaye Jack | -2,645 | - | - |
| 2026-06-03 | Kaye Jack | -2,645 | $30.01 | $79,376 |
| 2026-06-03 | Kaye Jack | +2,645 | $16.04 | $42,426 |
| 2026-05-08 | Abi-Saab Walid | -25,000 | - | - |
| 2026-05-08 | Abi-Saab Walid | -20,000 | $25 | $500,000 |
| 2026-05-08 | Abi-Saab Walid | -25,000 | $25.1 | $627,500 |
| 2026-05-08 | Abi-Saab Walid | +25,000 | $5.59 | $139,750 |
| 2026-03-04 | O'Keefe Kylie | +31,900 | - | - |
| 2026-03-04 | O'Keefe Kylie | +19,800 | - | - |
| 2026-03-04 | Abi-Saab Walid | +67,200 | - | - |
| 2026-03-04 | Abi-Saab Walid | -808 | $9.06 | $7,320 |
| 2026-03-04 | Abi-Saab Walid | +41,700 | - | - |
| 2026-03-04 | Potts Jeannette | +57,200 | - | - |
| 2026-03-04 | Potts Jeannette | -3,412 | $9.06 | $30,913 |
| 2026-03-04 | Potts Jeannette | +35,400 | - | - |
| 2026-03-04 | KLEMT CHRISTIAN | +63,900 | - | - |
| 2026-03-04 | KLEMT CHRISTIAN | -12,000 | $9.06 | $108,720 |
| 2026-03-04 | KLEMT CHRISTIAN | +39,600 | - | - |
| 2026-03-04 | Kapusta Matthew C | +113,800 | - | - |
| 2026-03-04 | Kapusta Matthew C | -14,581 | $9.06 | $132,104 |
| 2026-03-04 | Kapusta Matthew C | +70,600 | - | - |
| 2026-03-02 | KLEMT CHRISTIAN | -12,532 | $9.95 | $124,693 |
| 2026-03-02 | Potts Jeannette | -8,578 | $9.95 | $85,351 |
| 2026-03-02 | Abi-Saab Walid | -1,660 | $9.95 | $16,517 |
| 2026-03-02 | Kapusta Matthew C | -34,437 | $9.95 | $342,648 |
| 2026-02-25 | KLEMT CHRISTIAN | -6,217 | $23.86 | $148,338 |
| 2026-02-25 | Kapusta Matthew C | -12,378 | $23.86 | $295,339 |
| 2026-01-12 | Gut Robert | -17,810 | - | - |
| 2026-01-12 | Gut Robert | -7,803 | $25.09 | $195,777 |
| 2026-01-12 | Gut Robert | -500 | $25.03 | $12,515 |
| 2026-01-12 | Gut Robert | -17,310 | $24.39 | $422,191 |
| 2026-01-12 | Gut Robert | +17,810 | $14.08 | $250,765 |
| 2026-01-09 | Kaye Jack | -6,390 | - | - |
| 2026-01-09 | Kaye Jack | -6,390 | $27.28 | $174,319 |
| 2026-01-09 | Kaye Jack | +6,390 | $19.39 | $123,902 |
| 2025-11-06 | Gut Robert | -15,840 | - | - |
| 2025-11-06 | Gut Robert | -15,594 | $27.3 | $425,716 |
| 2025-11-06 | Gut Robert | -15,840 | $27.22 | $431,165 |
| 2025-11-06 | Gut Robert | +15,840 | $4.57 | $72,389 |
| 2025-11-04 | Kaye Jack | -17,810 | - | - |
| 2025-11-04 | Kaye Jack | -11,000 | - | - |
| 2025-11-04 | Kaye Jack | -10,000 | - | - |
| 2025-11-04 | Kaye Jack | -17,810 | $30.33 | $540,177 |
| 2025-11-04 | Kaye Jack | +17,810 | $14.08 | $250,765 |
| 2025-11-04 | Kaye Jack | -11,000 | $30.34 | $333,740 |
| 2025-11-04 | Kaye Jack | +11,000 | $5.37 | $59,070 |
| 2025-11-04 | Kaye Jack | -10,000 | $30.36 | $303,600 |
| 2025-11-04 | Kaye Jack | +10,000 | $7.37 | $73,700 |